SG10202102198RA - Treatment of multiple sclerosis with chs-131 - Google Patents
Treatment of multiple sclerosis with chs-131Info
- Publication number
- SG10202102198RA SG10202102198RA SG10202102198RA SG10202102198RA SG10202102198RA SG 10202102198R A SG10202102198R A SG 10202102198RA SG 10202102198R A SG10202102198R A SG 10202102198RA SG 10202102198R A SG10202102198R A SG 10202102198RA SG 10202102198R A SG10202102198R A SG 10202102198RA
- Authority
- SG
- Singapore
- Prior art keywords
- effective amount
- therapeutically effective
- compound
- multiple sclerosis
- milligrams
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394046P | 2016-09-13 | 2016-09-13 | |
| US201662436356P | 2016-12-19 | 2016-12-19 | |
| US201762460868P | 2017-02-19 | 2017-02-19 | |
| US201762491071P | 2017-04-27 | 2017-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202102198RA true SG10202102198RA (en) | 2021-04-29 |
Family
ID=61619253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102198RA SG10202102198RA (en) | 2016-09-13 | 2017-09-13 | Treatment of multiple sclerosis with chs-131 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190224186A1 (enExample) |
| EP (1) | EP3512512A4 (enExample) |
| JP (1) | JP2019531286A (enExample) |
| KR (1) | KR20190064583A (enExample) |
| CN (1) | CN110461318A (enExample) |
| AU (1) | AU2017326261A1 (enExample) |
| BR (1) | BR112019004791A2 (enExample) |
| CA (1) | CA3036694A1 (enExample) |
| IL (1) | IL265259A (enExample) |
| MX (1) | MX2019002901A (enExample) |
| SG (1) | SG10202102198RA (enExample) |
| WO (1) | WO2018053040A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| EA201992364A1 (ru) * | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| MX2015004564A (es) * | 2012-10-12 | 2015-07-21 | Teva Pharma | Laquinimod para producir el daño talamico en la esclerosis multiple. |
| HK1218510A1 (zh) * | 2013-01-30 | 2017-02-24 | Intekrin Therapeutics, Inc. | 用於治療多發性硬化症的PPARγ激動劑 |
-
2017
- 2017-09-13 BR BR112019004791A patent/BR112019004791A2/pt not_active Application Discontinuation
- 2017-09-13 EP EP17851479.0A patent/EP3512512A4/en not_active Withdrawn
- 2017-09-13 US US16/333,171 patent/US20190224186A1/en not_active Abandoned
- 2017-09-13 JP JP2019513922A patent/JP2019531286A/ja active Pending
- 2017-09-13 SG SG10202102198RA patent/SG10202102198RA/en unknown
- 2017-09-13 WO PCT/US2017/051414 patent/WO2018053040A1/en not_active Ceased
- 2017-09-13 MX MX2019002901A patent/MX2019002901A/es unknown
- 2017-09-13 CN CN201780069826.5A patent/CN110461318A/zh not_active Withdrawn
- 2017-09-13 CA CA3036694A patent/CA3036694A1/en not_active Abandoned
- 2017-09-13 KR KR1020197009963A patent/KR20190064583A/ko not_active Ceased
- 2017-09-13 AU AU2017326261A patent/AU2017326261A1/en not_active Abandoned
-
2019
- 2019-03-10 IL IL265259A patent/IL265259A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110461318A (zh) | 2019-11-15 |
| IL265259A (en) | 2019-05-30 |
| JP2019531286A (ja) | 2019-10-31 |
| EP3512512A1 (en) | 2019-07-24 |
| CA3036694A1 (en) | 2018-03-22 |
| KR20190064583A (ko) | 2019-06-10 |
| EP3512512A4 (en) | 2020-06-03 |
| AU2017326261A1 (en) | 2019-04-04 |
| US20190224186A1 (en) | 2019-07-25 |
| BR112019004791A2 (pt) | 2019-06-04 |
| WO2018053040A1 (en) | 2018-03-22 |
| MX2019002901A (es) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| IL252296A0 (en) | Methods for treating multiple sclerosis | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| GB201608885D0 (en) | Treatment | |
| IL256207B (en) | Methods for treating multiple sclerosis | |
| IL285882A (en) | Medicinal uses for l–4–chlorokynurenine | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| PT3661491T (pt) | 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica | |
| IL254155A0 (en) | pain treatment | |
| IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
| IL255498A (en) | Treatment of pruritus | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| IL269681A (en) | New methods for treating multiple sclerosis | |
| SI3307267T1 (sl) | Zdravljenje multiple skleroze | |
| GB201514729D0 (en) | Treatment of haemorrhoids | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| EP3294889A4 (en) | Multiple sclerosis treatment | |
| GB201512139D0 (en) | Methods of treatment | |
| HK40012003A (zh) | 用chs-131治疗多发性硬化症 | |
| SG11201704282UA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| GB201603752D0 (en) | Treatment of hypothyroidism | |
| GB201603755D0 (en) | Treatment of hypothyroidism | |
| SG10201913141UA (en) | Treatment of alphavirus-induced inflammation |